Alcidion has raised capital
Alcidion Group Ltd. (ASX:ALC) has raised capital via an institutional placement. The placement was well supported by existing shareholders whilst also welcoming several new institutional shareholders to the register. Proceeds from the raise will provide Alcidion with maximum flexibility and ensure a strong balance sheet to execute on its market opportunities and enable the firm to continue to drive revenue growth.
Alcidion is a market leading healthcare software informatics company providing an innovative technology platform to improve the efficiency and quality of patient care. Its flagship platform, Miya Precision, can be deployed in a modular approach to accommodate varying customer priorities and budget profiles across the UK, Australia and New Zealand markets.
At the end of September 2023, Alcidion had A$35.3 million (US$23m) of contracted revenue for FY24 (expected to grow over the remainder of the year) and is forecasting to be EBITDA and cashflow positive.
Oaklins’ team in Australia acted as lead manager in this transaction.
Contacter l'équipe de la transaction
Justin Lewis
Oaklins Henslow
Transactions connexes
MEDIK Hospital Design Group has been acquired by STERIS
The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.
En apprendre plusElectro Optic Systems has acquired the UK interceptor business of MARSS
Electro Optic Systems Holdings Limited (ASX: EOS) has acquired the UK-based interceptor unmanned aerial system business of MARSS Group for US$6.4 million (€5.5 million). The interceptor is a reusable electric drone effector guided by imaging sensors and AI, which EOS will integrate into its counter-drone portfolio for defense and critical infrastructure customers. EOS plans further investment to complete development.
En apprendre plusbioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.
En apprendre plus